Drreddys Laboratories reported $360M in Cash and Equivalent for its second fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cash And Equivalent Change
Ani Pharmaceuticals ANIP:US $ 24.26M 0.81M
Aurora Cannabis Inc ACB:CN 470.24M 85.85M
Bayer BAYN:GR € 3389M 2161M
Canopy Growth Corp WEED:CN C$ 192.56M 525.51M
Catalent CTLT:US $ 896M 92.1M
Corcept Therapeutics CORT:US $ 95.43M 43.05M
Drreddys Laboratories RDY:US $ 360M 144M
Endo International Ordinary Shares ENDP:US $ 1545.17M 117.4M
GlaxoSmithKline GSK:LN 3503M 1254M
Gw Pharmaceuticals GWPH:US $ 458.1M 28.65M
Hikma Pharmaceutical HIK:LN 2M 321M
Horizon Pharma HZNP:US $ 812.32M 0.71M
Lannett LCI:US $ 93.29M 12M
Lonza Group LONN:SW 501M 6M
Novartis NOVN:VX SF 5117M 1316M
Pacira Pharmaceuticals PCRX:US $ 105.77M 39.08M
Phibro Animal Health PAHC:US $ 50.21M 1.11M
Prestige Brands PBH:US $ 163.62M 131.32M
Richter Gedeon RICHT:HB 40.84B 50.61B
Supernus Pharmaceuticals SUPN:US $ 223.77M 31.87M
Teva Pharmaceutical TEVA:IT 2.44B 693M